All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the MPN Advocates Network.
The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by GSK, Novartis, AOP, Sobi and Takeda and supported through independent educational grants from Bristol Myers Squibb, Blueprint Medicines, Incyte and Merck Sharp & Dohme LLC, Rahway, NJ, USA. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View MPN content recommended for you
Results from a cross-study analysis of three prospective phase II trials (Japan, NCT04182100; China, NCT05485948; Korea, KCT0006138) evaluating ropeginterferon alfa-2b in 177 patients with polycythemia vera (PV) were published in Leukemia & Lymphoma by Hunter et al. The trials in China and Korea used a higher initial dose and accelerated titration (HIDAT) regimen, while the study in Japan used the slow titration regimen. Key endpoints included phlebotomy-free hematocrit (Hct) response rate, annualized phlebotomy frequency, complete hematologic response (CHR), and JAK2V617F variant allele frequency (VAF) change.
Key data: The phlebotomy-free Hct response rates were higher in Week 20–32 maintenance vs Week 0–32 (Japan, 79.31% vs 24.14%; China, 75.51% vs 30.61%; Korea, 66.67% vs 44.44%). In Weeks 0–32, higher phlebotomy-free Hct response rates were observed in studies using the HIDAT vs slow titration regimen (38.6% vs 24.1%; p < 0.0001), while the inverse was true in Weeks 20–32 (70.5% vs 79.3%; p < 0.0001). Mean annualized phlebotomy rates were lower in the pooled HIDAT cohort vs the slow titration cohort during Weeks 0–32 (0.37 vs 2.31 per year; p < 0.0001) and Weeks 20–32 (0.13 vs 0.60 per year; p = 0.0218); a greater proportion of patients receiving HIDAT vs slow titration were phlebotomy-free during Weeks 0–32 (86.6% vs 31.0%; p < 0.0001) and Weeks 20–32 (97.3% vs 86.2%; p < 0.0001). HIDAT was also associated with deeper JAK2V617F VAF reductions and higher CHR rates at 12 months. Both regimens were well tolerated, with serious adverse events occurring in 3.4%, 18.4%, and 11.1% of patients in the Japanese, Chinese, and Korean studies, respectively.
Key learning: Ropeginterferon alfa-2b provided durable Hct control and reduced phlebotomy dependence across a broad PV population, including high-risk patients. The HIDAT regimen was associated with more rapid and sustained phlebotomy-free responses; however, as comparisons are indirect and non-randomized, results should be interpreted with caution.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Do you include basal serum tryptase (bST) testing in the diagnostic evaluation of patients with MPN?